Citations

Showing 10 of 108119 citations.

Real-world outcomes associated with the use of the EmboTrap revascularization device for ischemic stroke in the United States
Brinjikji, Waleed , Ikeme, Shelly , Kottenmeier, Emilie , Khaled, Alia , Sidharth, M, Khanna, Rahul , Kottenmeier, Emilie

Mayo Clinic

Journal of NeuroInterventional Surgery | November 8, 2021 | Volume: 14 | Issue: 11 | Pages: 1068-1072

10.1136/neurintsurg-2021-018175 | PMID 34750107 Get It

Background Mechanical thrombectomy (MT) has become the standard of care for the treatment of acute ischemic stroke (AIS). The EmboTrap revascularization device (CERENOVUS, Johnson & Johnson Medical Devices, Irvine, California, USA) has an innovative, dual layer feature designed to facilitate thrombus retrieval. Objective To investigate the real-world clinical and economic outcomes among patients with AIS undergoing MT using the EmboTrap device in the United States (US). Methods Adult patients (≥18 years) who underwent MT for AIS using the EmboTrap device between July 2018 and December 2020 were identified from the Premier Healthcare Database. Patient outcomes included discharge status (including in-hospital mortality), mean length of stay (LOS), intracranial hemorrhage (ICH), mean hospital costs, and 30-day readmissions (all-cause, cardiovascular (CV)-related, and AIS-related). Results A total of 318 patients (mean age 68.5±14.6 years) with AIS treated with the EmboTrap device as the only stent retriever used were identified. Approximately 25% of patients were discharged to home/home health organization, and the in-hospital mortality rate was 10.7%. The rate of ICH was 16.7%. Mean hospital LOS was 9.9±11.3 days, and the mean hospital costs were US$47 367±30 297. The 30-day readmission rate was 9.6% for all-causes, 5.9% for CV-related causes, and 2.6% for AIS-related causes. Conclusions This is the first study in the US to report real-world outcomes sourced by retrospective database analysis among patients with AIS undergoing MT using the EmboTrap device. Further research is needed to better understand performance of the EmboTrap device in real-world settings.
Postpartum coronary artery embolism
Ezzeddine, Fatima M. , Hill, Meghan , Murphy, Joseph G. , Murphy, Joseph , Ezzeddine, Fatima , Alkhouli, Mohamad

Mayo Clinic

European Heart Journal - Case Reports | November 8, 2021 | Volume: 5 | Issue: 11 | Pages: No page available

10.1093/ehjcr/ytab456 | PMID 34870088 Get It

The Impact of Medications on Esophageal Motility
Snyder, Diana L. , Ravi, Karthik

Mayo Clinic

Foregut: The Journal of the American Foregut Society | November 8, 2021 | Volume: 1 | Issue: 3 | Pages: 277-285

10.1177/26345161211039434 Get It

The purpose of this review is to highlight the impact of common medications on esophageal motility. Esophageal motility is mediated through a complex network of neural innervation. Opioids lead to excitatory esophageal motor abnormalities termed opioid-induced esophageal dysfunction or OIED. Prokinetics have mixed effects on esophageal motility. Nitrates and calcium channel blockers relax esophageal smooth muscle, but they are limited clinically due to side effects. Sildenafil also relaxes smooth muscle, but it is costly. Peppermint oil may reduce distal esophageal spasm. Anticholinergics, selective serotonin reuptake inhibitors, estrogen, and cannabis need further study to evaluate their effects on esophageal motility.
Response to ‘An alternative method of establishing the first rib under ultrasound-guidance’
Hurdle, Mark Friedrich B., Ferreira‐Dos‐Santos, Guilherme , Rosario‐Concepción, Raúl A. , Gil, Laura V, Eldrige, Jason S. , Clendenen, Steven R. , Rosario-Concepcion, Raul, Clendenen, Steven R , Rosario-Concepcion, Raul A , Gil, Laura Velez

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 8, 2021 | Volume: 47 | Issue: 4 | Pages: 273.2-273

10.1136/rapm-2021-103254 | PMID 34750165 Get It

Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial
Omar, Massar , Jensen, Jesper , Burkhoff, Daniel, Frederiksen, Peter , Kistorp, Caroline , Videbæk, Lars, Poulsen, Mikael Kjær, Gustafsson, Finn , Køber, Lars, Borlaug, Barry A., Schou, Morten, Møller, Jacob Eifer, Køber, Lars , Poulsen, Mikael Kjær , Frederiksen, Peter H , Omar, Massar , Kistorp, Caroline , Gustafsson, Finn , Køber, Lars , Jensen, Jesper , Burkhoff, Daniel, Videbæk, Lars, Borlaug, Barry A., Schou, Morten, Møller, Jacob Eifer

Mayo Clinic

Circulation: Heart Failure | November 8, 2021 | Volume: 15 | Issue: 3 | Pages: No page available

10.1161/circheartfailure.121.009156 | PMID 34743533 Get It

Background: Stressed blood volume (SBV) is a major determinant of systemic and pulmonary venous pressures which, in turn, determine left and right ventricular fillings and regulates cardiac output via the Frank-Starling mechanism. It is not known whether inhibition of the SGLT2 (sodium–glucose cotransporter-2) favorably affects SBV. We investigated the effect of empagliflozin on estimated SBV in patients with heart failure and reduced ejection fraction compared with placebo. Methods: This was a post hoc analysis of an investigator-initiated, double-blinded, placebo-controlled, randomized trial. Seventy patients were assigned to empagliflozin 10 mg or matching placebo once daily for 12 weeks. Patients underwent right heart catheterization at rest and during exercise at baseline and follow-up. The outcome was change in estimated SBV after 12 weeks of empagliflozin treatment over the full range of exercise, determined using a recently introduced analytical approach based on invasive hemodynamic assessment. Results: Patients with heart failure and reduced ejection fraction, mean age, 57 years and mean ejection fraction 27%, with 47 patients (71%) receiving diuretics were randomized. The effect of empagliflozin on estimated SBV over the full range of exercise loads showed a statistically significant reduction compared with placebo (−198.4 mL [95% CI, −317.4 to −79.3] P =0.001), a 9% decrease. The decrease in estimated SBV by empagliflozin was significantly correlated with the decrease in PCWP ( R =−0.33, P <0.0001). The effect of empagliflozin was consistent across subgroup analysis. Conclusions: Empagliflozin treatment significantly reduced SBV compared with placebo after 12 weeks of treatment in patients with stable chronic heart failure and reduced ejection fraction during sub maximal exercise. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03198585.
Clioquinol Decreases Levels of Phosphorylated, Truncated, and Oligomerized Tau Protein
Lin, Gaoping, Zhu, Feiyan , Kanaan, Nicholas M. , Asano, Rei, Shirafuji, Norimichi, Sasaki, Hirohito, Yamaguchi, Tomohisa, Enomoto, Soichi, Endo, Yoshinori , Ueno, Asako , Ikawa, Masamichi , Hayashi, Kouji, Yamamura, Osamu , Yen, Shu‐Hui, Nakamoto, Yasunari , Hamano, Tadanori , Zhu, Feiyan

Mayo Clinic

International Journal of Molecular Sciences | November 8, 2021 | Volume: 22 | Issue: 21 | Pages: 12063

10.3390/ijms222112063 | PMID 34769495 Get It

The neuropathological hallmarks of Alzheimer’s disease (AD) are senile plaques (SPs), which are composed of amyloid β protein (Aβ), and neurofibrillary tangles (NFTs), which consist of highly phosphorylated tau protein. As bio-metal imbalance may be involved in the formation of NFT and SPs, metal regulation may be a direction for AD treatment. Clioquinol (CQ) is a metal-protein attenuating compound with mild chelating effects for Zn2+ and Cu2+, and CQ can not only detach metals from SPs, but also decrease amyloid aggregation in the brain. Previous studies suggested that Cu2+ induces the hyperphosphorylation of tau. However, the effects of CQ on tau were not fully explored. To examine the effects of CQ on tau metabolism, we used a human neuroblastoma cell line, M1C cells, which express wild-type tau protein (4R0N) via tetracycline-off (TetOff) induction. In a morphological study and ATP assay, up to 10 μM CQ had no effect on cell viability; however, 100 μM CQ had cytotoxic effects. CQ decreased accumulation of Cu+ in the M1C cells (39.4% of the control), and both total and phosphorylated tau protein. It also decreased the activity of c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) (37.3% and 60.7% levels of the control, respectively), which are tau kinases. Of note, activation of protein phosphatase 2A (PP2A), which is a tau phosphatase, was also observed after CQ treatment. Fractionation experiments demonstrated a reduction of oligomeric tau in the tris insoluble, sarkosyl soluble fraction by CQ treatment. CQ also decreased caspase-cleaved tau, which accelerated the aggregation of tau protein. CQ activated autophagy and proteasome pathways, which are considered important for the degradation of tau protein. Although further studies are needed to elucidate the mechanisms responsible for the effects of CQ on tau, CQ may shed light on possible AD therapeutics.
Evolving concepts in the perioperative management of obstructive sleep apnea after endoscopic skull base surgery
Rabinowitz, Mindy, Chaskes, Mark B., Thorp, Brian D. , Toskala, Elina , Nyquist, Gurston , Evans, James J., Choby, Garret , Wang, Eric W , Choby, Garret , Rosen, Marc R

Mayo Clinic

International Forum of Allergy & Rhinology | November 8, 2021 | Volume: 12 | Issue: 1 | Pages: 5-10

10.1002/alr.22905 | PMID 34747119 Get It

De novo hemorrhagic sporadic cavernous malformation appearance after COVID-19 respiratory infection: illustrative case
Holmes, Carmen R. , Flemming, Kelly D. , Flemming, Kelly D , Lanzino, Giuseppe

Mayo Clinic

Journal of Neurosurgery: Case Lessons | November 8, 2021 | Volume: 2 | Issue: 19 | Pages: No page available

10.3171/case21543 | PMID 36061975 Get It

BACKGROUND Little is known about whether coronavirus disease 2019 (COVID-19) influences cavernous malformation (CM) formation or hemorrhage risk. OBSERVATIONS The authors present the case of a 31-year-old patient who developed a hemorrhagic, de novo CM in the setting of a developmental venous anomaly within 3 months of COVID-19 respiratory disease. The authors speculate that COVID-19 disease stimulated formation of the CM through TLR4 inflammatory pathways and subsequently led to the hemorrhagic presentation because of hypercoagulability related to the disease. LESSONS This case raises the possibility that COVID-19 may be a risk factor for de novo development of CMs in predisposed patients.
ATU-4 E-health versus standard care in inflammatory bowel disease management: A systematic review and meta-analysis
Kuzhiyanjal, Anish John Kuriakose , Αντωνίου, Γεώργιος , Cross, Raymond, Limdi, Jimmy K. , Kuriakose Kuzhiyanjal, Anish J , Nigam, Gaurav , Farraye, Francis A.

Mayo Clinic

Abstracts of distinction | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A26.1-A26

10.1136/gutjnl-2021-bsg.45 Get It

PMO-31 Rapidity of ulcerative colitis symptom improvements during filgotinib induction: phase 2b/3 SELECTION study post-hoc analysis
Morison, Ben, Hibi∥, Toshifumi , Ritter, Timothy E., Dinoso, Jason B., Hsieh, Jeremy, Yun, Chohee , Zhao, Sally, Danese, Silvio , Zhang, Jie , Loftus, Edward V. , Rogler, Gerhard

Mayo Clinic

Posters | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A93.1-A93

10.1136/gutjnl-2021-bsg.170 Get It